Johnson & Johnson (NYSE:JNJ) is reportedly considering selling its stroke care unit, Cerenovus, in a deal that could value ...

Pharmaceutical giant Johnson & Johnson (JNJ) is planning to sell its stroke care business called “Cerenovus” for $1 billion ...

Johnson & Johnson is looking to sell its Cerenovus stroke therapy business, according three unnamed people "with knowledge of ...

J&J is exploring the sale of Cerenovus, a stroke care business, in a deal potentially worth $1 billion to $1.5 billion. The company spent over $30 billion on medtech acquisitions in the past three ...

U.S. pharmaceutical company Johnson & Johnson (JNJ) is planning to sell its stroke care business called “Cerenovus” for at least $1 billion U.S. The sale is part of Johnson & Johnson’s ongoing efforts ...

Johnson & Johnson aims to streamline operations by selling its stroke care business, Cerenovus, valued at $1B+.

Johnson & Johnson (NYSE:JNJ), the New Jersey-based healthcare company, is planning to sell its stroke care business, ...

Putting up Cerenovus, which manufactures surgical equipment used to treat stroke patients, up for sale, is part of J&J’s attempts to reorganize its medical technology division. According to the ...